CTOR
Citius Oncology, Inc.
Set alert
0.55 USD +0.02 +4.63%
0.5001 Day range 0.563
0.493 52-week range 1.75
- YTD
- -44.60%
- 1 year
- -67.98%
- Open
- 0.5274
- Prev close
- 0.5295
- Mkt cap
- 58.59M
- Vol
- 292.79K
- Avg vol
- 116.09K
- EPS
- -0.48
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.5001
- High
- 0.563
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.37
- Inst. own
- 0.70%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.13
- 200-d avg
- 7.55
- 1y target
- 3.00
Key statistics
- Market cap
- 69.88M
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.89
- EPS (TTM)
- -0.18
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 7.11M
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -85.28%
- Shares outstanding
- 71.30M
- Short % of float
- 0.00%
- 50-day average
- 1.13
- 200-day average
- 7.55
Analyst view
Consensus: none
Price target (mean) 3.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
CTOR Revenue — quarterly 1.49M
CTOR Net income — quarterly -8.92M
CTOR EPS — quarterly -0.08
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 27, 2024 | Maxim Group | init | — | Buy |
| Aug 13, 2024 | EF Hutton | main | Buy | Buy |
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
News
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
- Citius Oncology Reports Preliminary Q4 FY2026 LYMPHIR Wholesaler Unit Sales More Than Doubling 120% To 792 Units, With 950 Institutional Vial Orders And 54 Institutions Ordering The CTCL Treatment
- Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
- Citius Pharmaceuticals to Participate in October 2026 Investor Conferences
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why HIVE Digital Technologies Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
- Citius Oncology Q3 EPS $(0.08), Inline, Sales $1.494M Miss $2.500M Estimate
Your note
Sign in to keep a note on CTOR — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Yakira Capital Management, Inc. | 0.66% | 15,499 | 15.19K | Sep 29, 2024 |
| Virtu Financial LLC | 0.44% | 10,291 | 10.09K | Sep 29, 2024 |
| Osaic Holdings Inc | 0.23% | 5,480 | 5.37K | Sep 29, 2024 |
| UBS Group AG | 0.07% | 1,632 | 1.60K | Sep 29, 2024 |
| Bank of America Corporation | 0.01% | 160 | 156 | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.00% | 41 | 40 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.10% | 2,332 | 2.29K | Oct 30, 2024 |